-+ 0.00%
-+ 0.00%
-+ 0.00%

Rezera reports Phase 1 data showing high CNS exposure for NLRP3 inhibitor trabzanoflast

PUBT·09/30/2026 14:31:15
Rezera reports Phase 1 data showing high CNS exposure for NLRP3 inhibitor trabzanoflast
  • Sanofi Ventures portfolio company Rezera reported Phase 1 topline results for oral NLRP3 inhibitor trabzanoflast in healthy volunteers.
  • Trial showed the drug was generally well tolerated, with no serious adverse events or discontinuations.
  • Continuous cerebrospinal fluid sampling showed high CNS exposure, with Kp,uu of 1.9.
  • Data supported continued clinical development, with pharmacodynamic readouts indicating target engagement in CSF and blood.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi Ventures published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.